<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytochrome P450 3A (including 3A4) inhibitors and inducers</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytochrome P450 3A (including 3A4) inhibitors and inducers</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cytochrome P450 3A (including 3A4) inhibitors and inducers</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Strong inhibitors</td> <td class="subtitle1_left border_right_thick">Moderate inhibitors</td> <td class="subtitle1_left">Strong inducers</td> <td class="subtitle1_left">Moderate inducers</td> </tr> <tr> <td> <ul> <li>Adagrasib</li> <li>Atazanavir</li> <li>Ceritinib</li> <li>Clarithromycin</li> <li>Cobicistat and cobicistat-containing coformulations</li> <li>Darunavir</li> <li>Idelalisib</li> <li>Indinavir</li> <li>Itraconazole</li> <li>Ketoconazole</li> <li>Levoketoconazole</li> <li>Lonafarnib</li> <li>Lopinavir</li> <li>Mifepristone<sup>*</sup></li> <li>Nefazodone</li> <li>Nelfinavir</li> <li>Nirmatrelvir-ritonavir</li> <li>Ombitasvir-paritaprevir-ritonavir</li> <li>Ombitasvir-paritaprevir-ritonavir plus dasabuvir</li> <li>Posaconazole</li> <li>Ritonavir and ritonavir-containing coformulations</li> <li>Saquinavir</li> <li>Tucatinib</li> <li>Voriconazole</li> </ul> </td> <td class="border_right_thick"> <ul> <li>Amiodarone<sup>¶</sup></li> <li>Aprepitant</li> <li>Berotralstat</li> <li>Cimetidine<sup>¶</sup></li> <li>Conivaptan</li> <li>Crizotinib</li> <li>Cyclosporine<sup>¶</sup></li> <li>Diltiazem</li> <li>Duvelisib</li> <li>Dronedarone</li> <li>Erythromycin</li> <li>Fedratinib</li> <li>Fluconazole</li> <li>Fosamprenavir</li> <li>Fosaprepitant<sup>¶</sup></li> <li>Fosnetupitant-palonosetron</li> <li>Grapefruit juice</li> <li>Imatinib</li> <li>Isavuconazole (isavuconazonium sulfate)</li> <li>Lefamulin</li> <li>Letermovir</li> <li>Netupitant</li> <li>Nilotinib</li> <li>Ribociclib</li> <li>Schisandra</li> <li>Verapamil</li> </ul> </td> <td> <ul> <li>Apalutamide</li> <li>Carbamazepine</li> <li>Encorafenib</li> <li>Enzalutamide</li> <li>Fosphenytoin</li> <li>Lumacaftor</li> <li>Lumacaftor-ivacaftor</li> <li>Mitotane</li> <li>Phenobarbital</li> <li>Phenytoin</li> <li>Primidone</li> <li>Rifampin (rifampicin)</li> </ul> </td> <td> <ul> <li>Bexarotene</li> <li>Bosentan</li> <li>Cenobamate</li> <li>Dabrafenib</li> <li>Dexamethasone<sup>Δ</sup></li> <li>Dipyrone</li> <li>Efavirenz</li> <li>Elagolix, estradiol, and norethindrone therapy <span class="nowrap_whitespace">pack<sup>◊</sup></span></li> <li>Eslicarbazepine</li> <li>Etravirine</li> <li>Lorlatinib</li> <li>Mitapivat</li> <li>Modafinil</li> <li>Nafcillin</li> <li>Pexidartinib</li> <li>Repotrectinib</li> <li>Rifabutin</li> <li>Rifapentine</li> <li>Sotorasib</li> <li>St. John's wort</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>For drug interaction purposes, the inhibitors and inducers of CYP3A metabolism listed above can alter serum concentrations of drugs that are dependent upon the CYP3A subfamily of liver enzymes, including CYP3A4, for elimination or activation.</li>
<li>These classifications are based upon US Food and Drug Administration (FDA) <span class="nowrap_whitespace">guidance.<sup>[1,2]</sup></span> Other sources may use a different classification system resulting in some agents being classified differently.</li>
<li>Data are for systemic drug forms. Degree of inhibition or induction may be altered by dose, method, and timing of administration.</li>
<li>Weak inhibitors and inducers are not listed in this table with exception of a few examples. Clinically significant interactions can occasionally occur due to weak inhibitors and inducers (eg, target drug is highly dependent on CYP3A4 metabolism and has a narrow therapeutic index). Accordingly, specific interactions should be checked using a drug interaction program such as the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</li>
<li>Refer to UpToDate topics on specific agents and indications for further details.</li>
</ul></div><div class="graphic_footnotes"><p>* Mifepristone is a significant inhibitor of CYP3A4 when used chronically (eg, for hyperglycemia in patients with Cushing syndrome); not in single-dose use.</p>
<p>¶ Classified as a weak inhibitor of CYP3A4 according to FDA <span class="nowrap_whitespace">system.<sup>[1]</sup></span></p>
<p>Δ Classified as a weak inducer of CYP3A4 according to FDA <span class="nowrap_whitespace">system.<sup>[1]</sup></span></p>
◊ The fixed-dose combination therapy pack taken in the approved regimen has moderate CYP3A4 induction effects. When elagolix is used as a single agent, it is a weak CYP3A4 inducer. Norethindrone and estradiol are not CYP3A4 inducers.</div><div class="graphic_reference"><p>Data from: Lexicomp Online (Lexi-Interact). Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p>
References:
<ol>
<li>Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry (January 2020) available at: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions</a>.</li>
<li>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: <a href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm" target="_blank">FDA.gov website</a>.</li>
</ol></div><div id="graphicVersion">Graphic 76992 Version 98.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
